Acute Covid Pneumonia
Frequency and characteristics of acute Covid
COVID is a new viral respiratory illness that emerged in December 2019 and quickly spread around the world. For more details, refer to Wikipedia. The global epidemic continues to be active and to infect and kill many people daily.
The combination of different antivirals and/or monoclonal antibodies is recommended for patients at risk but not requiring oxygen. For patients in respiratory distress intensive care treatment with massive doses of oxygen is necessary.
HBOT clinical studies
- 2020: 5 patients with breathing difficulties despite high-dose oxygen received 1 to 6 sessions of HBOT to try to spare them an intubation. All patients were able to avoid mechanical ventilation. Their condition quickly normalized.
- 2020: HBOT found to be effective in 2 other cases.
- 2020: Intensive care was found to be much more effective with than without HBOT.
- 2022: In this comparative study, HBOT has no effect on mortality or on the rate of intubation, but dramatically shortened the period of respiratory distress and its recovery time with only 5 sessions. The pressure of 1,45 ATA used was lower than in other studies.
- 2022: 50 intensive patients treated with cortisone and antivirals received HBOT. After 3 daily sessions of 30 minutes each at 2.0 ATA pressure, the partial oxygen gradually increased, thus avoiding severe respiratory failure.
- 2022: 20 patients with COVID pneumonia were treated with and without HBOT. There were no deaths in the HBOT group but 3 in the without HBO.
Practical use of HBOT
Currently, 3 to 6 sessions are recommended for patients resistant to cortisone and antiviral treatment and to massive doses of oxygen.